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Human antibody responses are established by the generation of combinatorial sequence diversity 21 
in antibody variable domains, followed by iterative rounds of mutation and selection via T cell 22 
recognition of antigen peptides presented on MHC-II. Here, we report that MHC-II peptide epitope 23 
deletion from B cell receptors (BCRs) correlates with antibody development in vivo. Large-scale 24 
antibody sequence analysis and experimental validation of peptide binding revealed that MHC-II 25 
epitope removal from BCRs is linked to genetic signatures of T cell help, and donor-specific 26 
antibody repertoire modeling demonstrated that somatic hypermutation selectively targets the 27 
personalized MHC-II epitopes in antibody variable regions. Mining of class-switched sequences 28 
and serum proteomic data revealed that MHC-II epitope deletion is associated with antibody class 29 
switching and long-term secretion into serum. These data suggest that the MHC-II peptide epitope 30 
content of a BCR is an important determinant of antibody maturation that shapes the composition 31 
and durability of humoral immunity. 32 
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• Antibody somatic hypermutation selectively removes MHC-II peptide epitopes from B 38 
cell receptors. 39 
• Antibodies with lower MHC-II epitope content show evidence of greater T cell help, 40 
including class-switching. 41 
• MHC-II peptide epitope removal from a BCR is linked to long-term antibody secretion in 42 
serum. 43 
• MHC-II genotype provides a personalized selection pressure on human antibody 44 
development.  45 
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Human antibody adaptive immune responses are somatically generated by a Darwinian 47 
selection process via the generation of high genetic diversity in B lineage cells, followed by 48 
iterative rounds of selection with continued diversification. As B cells develop, first heavy chain 49 
V-(D)-J recombination occurs, followed by the light chain V-J recombination, to achieve 50 
tremendous combinatorial antibody diversity. The selection of antibodies with optimal 51 
characteristics from this highly diverse pool is achieved by several well-described mechanisms. 52 
First, self-reactive antibodies are negatively selected prior to the generation of the fully mature B 53 
cells (also called the naïve B cell population) [1]. Next, B cells migrate to germinal centers and 54 
capture foreign protein antigens via B cell receptor (BCR)-mediated endocytosis and present 55 
antigen-derived peptides on Major Histocompatibility Class II (MHC-II) to CD4+ helper T cells 56 
in the course of classical T cell-dependent antibody maturation [2, 3]. In this process, captured 57 
antigen and BCR are endocytosed together and shuttled into the MHC-II peptide processing 58 
pathway for cell surface presentation as linear peptides in the peptide-binding grooves of MHC-II 59 
proteins [4, 5]. T cells recognize the peptides displayed on MHC-II proteins via T cell receptor 60 
(TCR) interactions. The display of peptide:MHC-II (pMHC-II) on B cells provides the critical 61 
molecular targets for the TCRs of activating CD4+ helper T cells to recognize and provide 62 
stimulatory signals that induce somatic hypermutation, antibody class-switching, and eventual 63 
transition to plasmablasts/plasma cells for long-lived antibody production [3, 5].  64 
Despite decades of study related to B cell developmental checkpoints, several critical questions 65 
remain in B cell development mechanisms. In particular, it is unclear why only some of the 66 
antibodies that bind to foreign antigens with high affinity are selected for clonal expansion, class-67 
switching, and maturation to plasma cells. The humoral immune compartment is highly polarized 68 
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and has capacity to contain relatively few (<10,000) representatives of unique antibody clones at 69 
a concentration above their affinity constant (KD); the vast majority of the >107 unique antibody 70 
sequences present in our cellular immune repertoires are not present in serum at an adequate 71 
concentration for functional activity [6, 7]. These data also suggest that the memory B cell (mBC) 72 
population targets a broader range of antigens than are recognized by serum antibodies [6, 8]. 73 
Plasma cells constitute the last stage in B cell development, when plasma cells stop dividing, 74 
downregulate surface MHC-II expression, and can persist in bone marrow and secrete antibodies 75 
continuously for many years. It remains unclear what molecular mechanisms lead to robust 76 
selection for long-lived serum antibodies versus memory B cell persistence in the cellular 77 
repertoire, although available evidence strongly suggests that some type of B cell imprinting 78 
process determines B cell fate [9-12]. 79 
Surface display of antigen-derived MHC-II epitopes is one critical determinant of B cell fate 80 
due to the need for B cells to obtain help from antigen-specific CD4+ helper T cells. The affinity 81 
of antigen peptides for binding to MHC-II plays a major role in regulating immune responses to 82 
foreign proteins, including monoclonal antibody drugs [13-15]. MHC-II molecules are encoded 83 
by three human leukocyte antigen (HLA) loci:  HLA-DR, -DQ, and -DP. Of these, HLA-DR is the 84 
most polymorphic [16], and is usually expressed at higher levels [17, 18]. It is unclear why anti-85 
antibody (or anti-idiotype) immune responses are not highly prevalent due to the very high 86 
diversity of somatically mutated human antibodies, including the substantial untemplated diversity 87 
of CDR3 regions, although highly homologous antibody sequences (including T regulatory cell 88 
epitopes, or Tregitopes) have been suggested to play a role in reducing anti-antibody immunity 89 
[19-21]. Methods for computational MHC binding prediction have continually improved in recent 90 
years, particularly for HLA-DR [22], and recent high-throughput proteomic elution data have 91 
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provided large experimental datasets as benchmarks to enhance prediction accuracy [23, 24]. 92 
Moreover, peptides derived from BCR proteins are commonly detected as self-peptides in MHC-93 
II elution experiments [25-27]. Despite these advances, the landscape of potential MHC-II peptide 94 
epitope content in healthy antibody repertoires has not yet been evaluated, partially due to the 95 
relevantly recent invention of methods for repertoire-scale analysis of complete, natively paired 96 
antibody heavy and light chains [28, 29].  97 
Given the high importance of MHC-II epitopes in controlling B cell selection via MHC-II 98 
interactions, we hypothesized that MHC-II epitopes in BCR-encoded peptides could influence 99 
antibody selection and maturation. To explore these features, we analyzed potential MHC-II 100 
epitopes in the variable region sequences of human antibody repertoires to understand how 101 
antibody repertoire features correlate with MHC-II epitopes and may be influenced by a person’s 102 
unique HLA gene profile. Our analysis of seven natively paired heavy and light chain antibody 103 
repertoires from healthy human donors revealed that antibodies show hallmarks of selective 104 
removal of MHC-II peptide epitopes via somatic hypermutation throughout antibody 105 
development. By studying the MHC-II epitope content of BCRs along with molecular signatures 106 
of CD4+ T cell help (e.g., somatic hypermutation, antibody isotype class-switching, and serum 107 
proteomic detection), we found that the preferential deletion of MHC-II epitopes from the antibody 108 
variable regions was associated with B cells achieving the critical T cell help needed for robust 109 
and long-lived antibody immune memory. These data reveal a new mechanism regulating human 110 
antibody immunity and provide insights for the design of new vaccines and therapeutics associated 111 
with long-term immune memory.  112 
  113 
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We began by characterizing MHC-II peptide epitope content in healthy human antibody 115 
variable region sequences using high-throughput computational MHC-II peptide epitope 116 
prediction. We collected seven paired heavy and light chain datasets from antigen-experienced B 117 
cells of healthy donors, with a total of 250,645 high-quality consensus sequences of natively paired 118 
heavy and light chain antibody lineages. We analyzed these immune repertoires using multiple 119 
pMHC-II affinity prediction algorithms to determine how the features of antibody development 120 
correlated with changes in potential MHC-II peptide epitope content of BCRs (Fig. 1A). First, we 121 
used the commercially available EpiMatrix MHC-II epitope prediction platform to characterize 122 
aggregate predicted HLA-DR epitope content based on eight human HLA-DR gene supertypes. 123 
EpiMatrix reports a T cell epitope score, where a higher score indicates higher content of putative 124 
MHC-II peptide epitopes within the analyzed protein sequence [30]. Strikingly, we noted that all 125 
donors showed reduced MHC-II peptide epitope content (i.e., reduced EpiMatrix scores) that was 126 
correlated with increasing somatic hypermutation (SHM), and the correlation was statistically 127 
significant in all donors (Spearman correlation test, adjusted p-value < 0.05). These data 128 
demonstrated that SHM reduces pMHC-II affinities in antibody peptides at a repertoire level (Figs. 129 
1B, S1A). Subsequent analysis of antibody repertoire data fractionated by paired antibody heavy 130 
and light chain V-genes showed that changes in MHC-II peptide epitope content were concentrated 131 
in certain V-gene combinations (Figs. 1C, 1D, S1B, S1C), and each V-gene shows a different 132 
initial distribution of MHC-II peptide epitope content (Fig. S2). While each donor showed a unique 133 
pattern of V-genes with the highest reductions in MHC-II peptide epitope content, some V-genes 134 
were repeatedly observed as statistically significant across donors. Nearly all statistically 135 
.CC-BY-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted January 17, 2021. ; https://doi.org/10.1101/2021.01.15.426750doi: bioRxiv preprint 
 
 
significant V-gene changes showed removal of MHC-II peptide epitopes as SHM levels increased 136 
(Fig. 1, Fig. S1). 137 
We next sought to understand the molecular drivers of decreased MHC-II peptide epitope 138 
content based on personalized HLA gene profiles. We applied the netMHCIIpan algorithm to 139 
model individual MHC-II binding affinities of every peptide in our antibody datasets, according 140 
to the known HLA gene profiles that were available for donors 1 to 5 (Fig. 2) [31]. We found that 141 
several predicted high-affinity HLA-DR-binding peptides were encoded by antibody germline 142 
genes, and these MHC-II peptide epitopes were being mutated during antibody somatic 143 
hypermutation (Fig. 2A, S3). Thus, somatic hypermutation caused deletion of MHC-II peptide 144 
epitopes from B cell receptors, and the correlations that we observed in Figure 1 could be traced 145 
to specific peptides with a high germline (unmutated) affinity for the donor’s MHC-II genes. When 146 
comparing V-genes between germline and high SHM antibody sequences, the removal of high-147 
affinity MHC-II peptide epitopes by SHM was readily apparent (Figs. 2B, 2C, 2D, 2E, S4A, S4B, 148 
S4C, S4D). Thus, the reduction in MHC-II peptide epitope content that we observed with 149 
increasing SHM was predominantly driven by the deletion of high-affinity peptides that had been 150 
present since the earliest stages of antibody development.  151 
We next sought to experimentally confirm the loss of peptide affinities that were observed via 152 
in silico affinity modeling. We validated peptide affinity changes for key driver epitopes of MHC-153 
II epitope deletion using in vitro pMHC-II affinity assays (Fig. 2G). These data showed that, as in 154 
prior studies, large-scale in silico predictions of peptide binding to MHC-II are generally accurate, 155 
especially for the DRB1 gene used in the current study [31]. Next, we mined the Immune Epitope 156 
Database (IEDB) to identify antibody peptides eluted from human MHC-II in immunopeptidomic 157 
assays to see if our detected peptides successfully process inside endosomes and displayed on 158 
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MHC-II in vivo [32, 33]. We identified a large number of naturally-processed peptides that were 159 
experimentally confirmed in IEDB and appeared to be targets of preferential mutations that reduce 160 
peptide affinity via SHM, including peptides that were mutated in antibody sequence data such as 161 
IGHV3-2373-93 and IGHV1-1873-92 (Fig. 2E, Fig. S5A, S5B). Interestingly, donor antibody 162 
repertoires also contained some of the same peptides that were eluted from HLA-DP and HLA-163 
DQ molecules(Fig. S5B); numerous IEDB-validated peptides overlapped between DRB and 164 
DP/DQ binding (Fig. S5C). Thus we confirmed that some of the key peptides analyzed in our 165 
study are presented on human MHC-II in previously reported proteomic datasets.  166 
Once we realized that antibody peptides with high affinity for DRB binding were being 167 
targeted for mutations and MHC-II epitope removal, we shifted our focus to patient-specific 168 
analyses to explore these high-affinity MHC-II peptide epitopes encoded by germline IGHV and 169 
IGKV/IGLV genes (Fig. S6). MHC-II peptide epitopes often require multiple amino acid matches 170 
with appropriate spacing for binding to the MHC-II cleft, and we reasoned that the reduced T cell 171 
content observed with increasing SHM could be introduced as an indirect consequence of SHM 172 
mutational pattern preferences, rather than by active selection pressure. To test this alternate 173 
hypothesis, we reasoned that if MHC-II peptide epitopes are removed by SHM to a greater degree 174 
in experimentally-derived patient repertoires than in carefully matched in silico simulations (which 175 
account for SHM DNA motif targets, but not for any HLA-dependent MHC-II peptide epitope 176 
selection pressure), then we could conclude that MHC-II epitope removal was a result of active 177 
selection in vivo. We thus began large-scale in silico experiments simulating antibody repertoires 178 
using established somatic hypermutation models (Figs. 3, S7). We compared two different SHM 179 
models to the experimentally-derived sequence data:  one in silico SHM model customized by the 180 
5-mer DNA base targeting patterns in each individual patient’s experimentally-derived antibody 181 
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repertoire, and a second in silico model based on 5-mer DNA bases in universal out-of-frame 182 
human B cell receptor data. Our out-of-frame model controls for the nucleotide targeting 183 
preferences of human activation-induced cytidine deaminase (AID), the enzyme responsible for 184 
SHM, as antibody DNA sequences with out-of-frame V-(D)-J junctions cannot be expressed or 185 
functionally selected, and it was constructed from approximately 56,000 genomic out-of-frame 186 
antibody sequences compiled from 114 donors [34, 35]. In contrast, the patient-specific in-frame 187 
antibody SHM model encompassed local AID 5-mer nucleotide preferences, in addition to 188 
biophysical restrictions on permissible DNA/amino acid mutations in functional B cell receptors, 189 
as along with any positive selection for 5-mer DNA mutations within a patient’s immune system. 190 
By comparing MHC-II peptide epitope deletion metrics in experimentally-derived antibody data 191 
versus in silico simulations, we found that in most cases the replacement-silent (R-S) model and 192 
universal out-of-frame (OoF) models showed a lower number of statistically significant IGHV and 193 
IGKV/IGLV gene pairs with decreased MHC-II peptide epitope content compared to 194 
experimentally-derived donor data (Figs. 3C, 3D, S8). Often, one donor HLA-DRB1 allele showed 195 
a greater degree of MHC-II epitope loss than the other allele. Comprehensive SHM computational 196 
models did not recreate the same degree of personalized MHC-II peptide epitope deletion observed 197 
in experimentally-derived donor data (Fig. 3E), confirming that the SHMs deleting pMHC-II 198 
epitopes in vivo were functionally selected and would not arise simply as a consequence of AID 199 
targeting preference. These data demonstrate the SHM preferentially deletes pMHC-II epitopes 200 
from BCR variable regions. 201 
Next, we tested whether MHC-I peptide epitopes were also being preferentially deleted. We 202 
predicted peptide KD for donor-matched MHC-I molecules to compare relative MHC-I and MHC-203 
II peptide affinity changes as a result of antibody somatic hypermutation. Because some peptides 204 
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bind to both MHC-I and MHC-II, we binned peptide epitopes according to binding for MHC-I, 205 
MHC-II, or both MHC-I+MHC-II to determine how T cell epitope removal via SHM affected the 206 
different MHC classes separately. In contrast to our analyses of MHC-II, the peptides predicted to 207 
bind to MHC-I showed very few statistically significantly changes when removing peptides that 208 
were shared epitopes with MHC-II (p<0.001, Wilcoxon rank sum test, Fig. 3F, upper panel). 209 
Moreover, unique MHC-I peptides showed a weaker correlation between KD fold-change and 210 
SHM compared to shared MHC-I/MHC-II peptides (p < 0.05, Wilcoxon rank sum test, Fig. 3F, 211 
lower panel). In contrast, we observed no significant difference between shared MHC-I/MHC-II 212 
peptides and MHC-II-restricted peptides. These data demonstrated that peptides binding to MHC-213 
II were targeted for preferential deletion from antibody variable regions via SHM, but peptides 214 
that bound to MHC-I did not show similar preferential removal via SHM. Thus, SHM appears to 215 
selectively target MHC-II peptide epitopes for deletion.  216 
Next, we analyzed our data by antibody isotype bins to further understand how MHC-II peptide 217 
epitope removal correlated with key markers of B cell development and CD4+ T cell help. Like 218 
SHM, antibody class switching is induced by AID and is strongly correlated with CD4+ T cell 219 
help obtained via pMHC-II:TCR interactions [36]. We found that the greatest correlation of MHC-220 
II peptide epitope deletion with SHM was observed in class-switched IgG and IgA repertoires 221 
(Figs. 4A, 4B). Analysis of class-switched data provided a clear association between MHC-II 222 
peptide epitope removal from antibody gene sequences with antibody class-switching, an 223 
important hallmark of effective CD4+ T cell help. 224 
Finally, we sought to understand how MHC-II peptide epitope content in BCRs is associated 225 
with elicitation of antibodies into the serum immune compartment. Serum antibodies are secreted 226 
by plasmablasts and long-lived plasma cells, and recent advances in antibody sequencing, 227 
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computational mining of BCR NGS data, and proteomic mass spectrometry have enabled the 228 
identification of individual antibody clonal lineages in human serum [7, 37-39]. We performed 229 
HLA-DRB1 MHC-II peptide binding affinity predictions using cellular-derived and serum-230 
derived antibody repertoire data from recent studies of influenza vaccination [40, 41]. We found 231 
that antibodies identified in serum exhibited lower MHC-II peptide epitope content than the 232 
antibodies present in the donor-matched cellular repertoire (Figs. 4C). Thus, a lower MHC-II 233 
epitope content in the BCR was associated with B cell maturation to plasmablasts and plasma cells 234 
for secretion of antibodies at appreciable concentrations into the blood compartment. We also 235 
tracked the MHC-II peptide epitope content of anti-influenza antibodies with different temporal 236 
persistence in human serum. We found that antibodies detected in serum at multiple time points 237 
showed lower MHC-II peptide epitope content relative to antibodies observed only at a single time 238 
point (Fig. 4D), implying that lower MHC-II peptide epitope content is associated with longer 239 
antibody-secreting cell life spans in vivo. These analyses of serum antibody data, together with our 240 
observations that class-switched IgG and IgA compared with donor-matched IgM repertoires, 241 
suggested that human BCRs are functionally selected to remove MHC-II epitopes via somatic 242 
hypermutation as a component of natural human antibody development. 243 
 244 
Discussion 245 
This study reveals that antibody maturation and somatic hypermutation are closely associated 246 
with the removal of MHC-II peptide epitope content in antibody and BCR molecules. We observed 247 
strong selection for the removal of MHC-II peptide epitopes by SHM in class-switched BCRs, and 248 
also in antibodies secreted persistently in human serum. These data reveal a previously unreported 249 
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mechanism for the personalization of antibody immune responses via functional selection 250 
according to each individual’s unique HLA MHC-II gene profile (Fig. 4E). 251 
Our study employed in silico and statistical techniques using computational HLA-DRB1 252 
MHC-II peptide binding predictions, which have been demonstrated to be generally accurate in 253 
several recent studies [42, 43]. To validate in silico results, we confirmed our findings with 254 
experimental validation of key MHC-II peptide predictions (Fig. 2G), by analysis of eluted 255 
peptides reported in the IEDB (Fig. S5), and by retrospective analysis of serum antibody data 256 
reported in prior studies (Figs. 4C, 4D) [40]. We focused on HLA-DRB1 genes, which have the 257 
highest observed prevalence among MHC-II receptor genes in immunopeptidome assays and 258 
IEDB datasets, and are the best-characterized MHC-II receptor genes for computational peptide 259 
affinity predictions. We note that not all donors showed the same extent of HLA-DRB1 genetic 260 
selection (Fig. 3). Variability between individuals could result from the influence of HLA-DP and 261 
HLA-DQ genes providing additional MHC-II epitope selection pressures, that were not 262 
encompassed by our study of HLA-DRB1 peptide epitopes. Many T-dependent antigens can elicit 263 
HLA-DP and HLA-DQ responses, although we also note that some peptide binding overlap exists 264 
between different HLA molecules. Improved in silico tools for predicting peptide processing, as 265 
well as the incorporation of HLA-DP and HLA-DQ modeling, will enhance future large-scale 266 
studies of pMHC-II content in antibody repertoires.  267 
Our data suggest that reduced MHC-II epitope content in BCRs could be an important correlate 268 
of durable human antibody immunity. These findings are supported by our observations that BCRs 269 
in class-switched isotypes (e.g., IgA and IgG that require high levels of T cell help) show stronger 270 
rates of MHC-II peptide epitope removal than the IgM compartment (Figs. 3A, 3B, S9). We also 271 
observed that lower BCR MHC-II peptide epitope content was associated with higher serum 272 
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antibody prevalence, suggesting that HLA-DRB1 peptide epitope deletion may support B cell 273 
trafficking to a long-lived plasma cell niche by enhancing the acquisition of T cell help (Fig. 4E) 274 
[44]. Certain heavy and light chain V-genes showed higher rates of HLA-DRB1 peptide epitope 275 
removal than other V-gene pairs (Fig. 2B), reflecting the different baseline levels of MHC-II 276 
peptide epitopes in antibody germline genes (Figs. S2, S3). These data suggest that MHC-II 277 
epitope deletion is targeted toward those V-genes that contain germline-encoded MHC-II epitopes, 278 
as would be expected to occur in a functional selection mechanism. Low MHC-II epitope content 279 
in a B cell receptor could help that B cell present more MHC-II epitopes from antigen, thereby 280 
enhancing CD4+ T cell help for that B cell (Fig. 4E). This selection mechanism offers several 281 
important advantages in vivo. First, selection of lower MHC-II peptide epitope content reduces the 282 
propensity of an individual’s secreted antibodies to induce CD4+ T-cell dependent anti-idiotype 283 
antibody immune responses in non-templated regions (e.g., from pMHC-II derived from CDR3 284 
loops, or that may arise as a result of SHM), reducing the risk of immune responses to somatically 285 
generated antibody proteins. Perhaps more importantly, low MHC-II peptide epitope content in an 286 
antibody could help dendritic cells present a greater fraction of MHC-II peptides derived from 287 
antigen (and fewer peptides derived from the BCR) after immune complex capture and processing. 288 
These findings have important implications for vaccine design and antibody drug therapeutics. As 289 
one example in HIV vaccine development, where targeted elicitation of specific lineage mutations 290 
are being pursued, these data suggest an important HLA-dependent selection pressure guiding 291 
SHM, and that antibody mutations may accumulate differently in patients with different HLA gene 292 
profiles due to MHC-II-based selection pressure [45, 46]. In addition, our findings lend further 293 
support to ongoing efforts to mitigate anti-drug antibody responses by removal of MHC-II peptide 294 
epitopes from the monoclonal antibody drug variable regions [47, 48] 295 
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One limitation of our study is that we analyzed only the HLA-DRB1 gene, due to its high 296 
representation in quantitative peptide:MHC-II proteomic elution studies and established predictive 297 
peptide binding accuracy [31]. Future studies will further analyze human HLA-DP and HLA-DQ 298 
genes, which have lower peptide elution prevalence in immunopeptidomic assays but still make 299 
important contributions to human immunity. We will also study the influence of SHM on 300 
previously reported regulatory MHC-II epitopes [19]. We recognize that T-cell independent B cell 301 
activation pathways also exist (especially for antigens with repeated structural motifs and that lack 302 
MHC-II epitopes, for example the regularly ordered polysaccharides in bacterial cell walls). 303 
However, most foreign antigens generate T-dependent immunity and we anticipate that the 304 
majority of human B cells are selected via T-dependent mechanisms. Follow-up studies will 305 
investigate dysregulation of MHC-II antibody selection pathways for specific antigens (including 306 
T-dependent and T-independent) in mouse models, and similar analyses of clinical samples from 307 
patients with autoimmune diseases known to disrupt antibody developmental checkpoints [49-51]. 308 
In summary, here we identified a previously unreported correlation between lower MHC-II 309 
peptide epitope content in BCRs and the signatures of T cell help throughout antibody 310 
development. These data suggest that an MHC-II-based selection pressure influences antibody 311 
selection in vivo, and may represent an important factor shaping the durability of serological 312 
immunity in humans [9, 44, 52].   313 
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Resource Availability  334 
Lead Contact 335 
Further information and requests for resources and reagents should be directed to and will be 336 
fulfilled by the Lead Contact, Dr. Brandon DeKosky (dekosky@ku.edu).  337 
 338 
Materials Availability 339 
No new reagents were generated in this study. 340 
 341 
Data and Code Availability 342 
Raw NGS antibody sequence data used for the study are deposited in the NCBI Short Read Archive 343 
under accession numbers: XXXX, XXXX, XXXX, XXXX. 344 
 345 
Experimental Model and Subject Details 346 
Human Subjects 347 
For cellular antibody MHC-II content, a total of seven datasets were analyzed. These include 348 
previously published data (Donors 1,2,4,6 and 7) [53][Fahad, DeKosky et al., Front. Immunol., 349 
Accepted 2021], and new unpublished datasets (Donors 3 and 5). All human samples were 350 
collected under the Vaccine Research Center’s (VRC)/National Institutes of Allergy and Infectious 351 
Diseases (NIAID)/ National Institutes of Health (NIH) sample collection protocol, VRC 200 352 
(NCT00067054) in compliance with the NIH IRB approved procedures. All subjects met protocol 353 
eligibility criteria and agreed to participate in the study by signing the NIH IRB approved informed 354 
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consent. Research studies with these samples were conducted by protecting the rights and privacy 355 
of the study participants.  356 
For cellular and serum antibody datasets, data was retrieved from previously published Ig-Seq 357 
and BCR-Seq data [40, 41]. The first dataset consists of IgG/A/M from B cell receptors and serum 358 
IgG antibody sequences that were obtained from donors after influenza vaccination, and is 359 
available in MassIVE (https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp) under accession 360 
ID MSV000080184. The published dataset comprise serum antibodies that were purified by 361 
affinity chromatography with inactivated components of the 2011–2012 IIV3 vaccine at days 0, 362 
28 and 180 post-vaccination and analyzed via proteomic mass spectrometry [40]. The second 363 
dataset contains clonotypes that were detected in serum as a response to repeated flu vaccinations 364 
during several years (MassIVE ID MSV000083120). In this case, the original study contemplated 365 
persistent, intermediate and transient categories; which were changed to single observation 366 
(transient in the original study) and multiple observations (persistent and intermediate) [41]. 367 
 368 
Cell Lines 369 
Drosophila S2 cells were grown at 100 rpm in 27 C incubator, with SF900 II serum-free medium 370 
(Thermo Fisher cat #10902096) and penicillin-streptomycin (100 U/ml Thermo Fisher cat # 371 
15140148). HLA-DR1 protein production was induced by addition of 1mM CuSO4 and culture 372 
supernatants were collected after 6 days.  373 
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Method Details 374 
Emulsion Overlap Extension RT-PCR 375 
 Natively paired antibody heavy and light chains sequencing was carried out as previously 376 
described [54]. B cell isolation from cryopreserved PBMCs was carried out using Memory B cells 377 
Isolation Kit (MACS/Miltenyi Biotec, Bergisch Gladbach, Germany). Next, cells were stimulated 378 
in vitro using IL-2, IL-21, and co-cultured with 3T3-CD40L fibroblasts for 5 days [55]. Following 379 
cell stimulation, single cells were captured in emulsion droplets, lysed, and their mRNA captured 380 
with oligo(dT)-coated magnetic beads. Native heavy and light chains were obtained by an overlap-381 
extension RT-PCR and resulting cDNA libraries were sent for Illumina sequencing.  382 
 383 
Antibody Sequence Analysis 384 
Illumina 2x300 bp sequencing was analyzed as previously described [55]. Briefly, Illumina 385 
reads were quality filtered and aligned into full reads. V(D)J annotation was carried out using 386 
IgBlast [56], and productive sequences were paired by CDR-H3 match. Isotype assignment was 387 
carried out by matching of constant region sequences to isotype barcodes. Consensus sequences 388 
of paired heavy and light chain clusters were generated as previously reported to remove NGS 389 
errors prior to MHC-II peptide epitope content predictions [29, 54, 57]. 390 
For serum and cellular antibody repertoire data, reported protein sequences were mapped to 391 
clonotypes by generating consensus VH sequences using the reported cluster identifier in the data, 392 
with a 80% identity threshold using usearch version 6.1.544 [58], and V(D)J annotation was 393 
carried out using IgBlast. Serum antibodies were retrieved from BCR-seq data by matching 394 
reported CDR-H3 sequences with the available BCR-seq data.  395 
 396 
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MHC Peptide Epitope Content Prediction 397 
The EpiMatrix tool (EpiVax, Rhode Island, USA) was used for aggregate MHC-II peptide 398 
epitope / T cell epitope predictions [30]. EpiMatrix uses main HLA II DRB1 “supertypes” to 399 
predict overall protein epitope content [59]. Higher scores in the EpiMatrix output indicate a higher 400 
probability of T cell dependent immunogenicity of foreign protein antigens. The alleles analyzed 401 
were DRB1*01:01, DRB1*03:01, DRB1*04:01,DRB1*07:01, DRB1*08:01, DRB1*09:01, 402 
DRB1*11:01, DRB1*1302 and DRB1*15:01. The output data includes aggregate epitope score 403 
by chain, normalized by length, and total antibody epitope content. We used the complete antibody 404 
epitope content, not corrected for Treg epitope content as a measure of immunogenicity. Spearman 405 
Rho correlations between complete antibody epitope scores and SHM were calculated, and a linear 406 
model was fitted to calculate slopes.  407 
For individual MHC-II peptide epitopes, netMHCIIpan 3.1 with default options was used, 408 
working with a subset of 38 representative HLA-DRB1 molecules DRB1*01:01, DRB1*01:02, 409 
DRB1*01:03, DRB1*03:01, DRB1*03:02, DRB1*04:01, DRB1*04:02, DRB1*04:03, 410 
DRB1*04:04, DRB1*04:05, DRB1*04:06, DRB1*04:07, DRB1*04:08, DRB1*07:01, 411 
DRB1*08:01, DRB1*08:02, DRB1*08:03, DRB1*08:04, DRB1*09:01, DRB1*10:01, 412 
DRB1*11:01, DRB1*11:02, DRB1*11:03, DRB1*11:04, DRB1*12:01, DRB1*12:02, 413 
DRB1*13:01, DRB1*13:02, DRB1*13:03, DRB1*13:05, DRB1*14:01, DRB1*14:02, 414 
DRB1*14:06, DRB1*15:01, DRB1*15:02, DRB1*15:03, DRB1*16:01, and DRB1*16:02 [31]. 415 
netMHCIIpan output was parsed using pandas for further processing. The equilibrium dissociation 416 
constant (KD) or rank of 15-mers was considered for analysis. As a consequence of this, higher 417 
netMHCIIpan KD reflect a lower level of MHC-II peptide epitope content. Peptide KD’s were 418 
predicted for donor repertoire MHC-II peptide epitopes, and for a database of germline heavy and 419 
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light chain V genes. Germline (unmutated) peptides with KD <1,000 nM for tested alleles were 420 
used as a search database for peptides in antibody repertoires by matching V-gene usage and index 421 
position within the protein [60]. Peptides hits were grouped according to parent antibody, 422 
considering heavy or light chains, and the geometric mean of KD fold-change between donor and 423 
germline peptides was calculated. The same procedure for calculating the geometric mean of KD 424 
fold-change was applied in a grouping by complete antibody (paired heavy and light chain) 425 
sequences. Next, data was grouped by common VH gene and VK/L gene pairs, and Spearman 426 
correlation between the geometric mean of KD fold-change and SHM was calculated for each 427 
allele.  428 
For position-based MHC-II peptide epitope content, we selected the top 5% of sequences in 429 
terms of SHM burden from the selected V-gene subset, and the geometric mean of the rank of each 430 
peptide at the same position was calculated for a subset of the antibody repertoire. The same 431 
approach was carried out for germline sequences. This information was also retrieved for selection 432 
of candidate peptides, shown as logo plots. 433 
For MHC-I peptide epitope prediction, netMHCpan 4.1 [24] was used, using donor-matched 434 
HLA-A, -B and -C genes and predicting binding affinity for 9-mers. Germline (unmutated) 435 
peptides with KD<500 nM for tested alleles were used as a search database for peptides in antibody 436 
repertoires by matching V-gene usage and index position within the protein [61].  437 
Determination of MHC-I/MHC-II shared epitopes was done by matching 9-mer peptides 438 
(MHC-I peptide epitopes, 6 HLA-I alleles) into 15-mers (MHC-II peptide epitopes, 2 HLA-II 439 
DRB1 alleles). Epitopes with a positive match were considered as shared epitopes and the 440 
unmatched peptides were considered as exclusively MHC-I or MHC-II peptide epitopes. From 441 
MHC-I or MHC-II all (no matching), shared and unique databases, peptides were aggregated into 442 
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parent antibodies as described previously. The number of significant VH:VL gene pairs was 443 
compared for MHC-I and MHC-II peptides separately.  444 
 445 
In silico Repertoire Modeling and Analysis 446 
Repertoire modeling was carried out with immuneSIM for V(D)J recombination modeling, 447 
and ShaZam for SHM modeling [62, 63]. First, V gene frequency was extracted from donor data 448 
and used to build V gene distribution table. This table was used to modify the vdj_list parameter 449 
in the immuneSIM function, which controls the frequency of different V-genes in the modeled 450 
repertoire. D and J gene distributions were maintained in their default settings. Using the custom 451 
V gene distribution frequencies, a naïve repertoire of the same size of the parent repertoire was 452 
generated, using the immuneSIM function, with no mutations allowed. Heavy and light chains 453 
were generated separately. The naïve dataset was mutated using SHM models from repertoire data 454 
generated by ShaZam, using the createTargetingModel function, which allows the determination 455 
of a 5-mer targeting model based on sequence data and gene annotation. Two SHM models were 456 
generated, one considering donor antibody repertoire data, and other built from out-of-frame (OoF) 457 
sequences from genomic antibody sequencing studies, comprising 115 donors, and 56,278 458 
sequences [34, 35]. Briefly, data from two genomic antibody sequencing studies were retrieved 459 
for the generation of a new OoF targeting mutational model. One dataset comprised large-scale 460 
genomic BCR sequencing of healthy donors (NCBI BioProject Accession number PRJNA491287) 461 
and another from a genomic B cell sequencing study of CAPRISA cohort donor CAP256 462 
(Accession number SRP124539) [35]. After aggregating data form the 115 donors, all NGS reads 463 
were quality filtered and aligned using MiXCR [64] to identify a combined total of 56,278 out-of-464 
frame antibody sequences that were used to build a mutational targeting model using ShaZam. 465 
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First, nucleotide sequences were analyzed with IgBlast , and the output was parsed into a Shazam-466 
compatible database using Change-O [62]. Compiled out-of-frame aggregate donor data and 467 
personalized in-frame donor antibody databases were transformed individually into a 5-mer 468 
mutational targeting model using the create TargetingModel function from ShaZam to generate 469 
the out-of-frame model (OoF) or the personalized replacement-silent mutational models, 470 
respectively. After mutational model generation, each sequence was mutated individually using 471 
the shmulateSeq function from ShaZam. The number of mutations per sequence was selected to 472 
match the distribution of SHM observed in personalized donor data, on an individual donor dataset 473 
basis. After each repertoire generation, sequences were annotated using IgBlast and paired 474 
following donor distributions of SHM between heavy and light chains. Each simulation was 475 
compared to parent repertoire to verify appropriate V-gene distributions and SHM content to match 476 
the experimental data. From the IgBlast output, amino acid sequences were extracted for MHC-II 477 
peptide epitope prediction using netMHCIIpan. 478 
We generated 30 complete simulated antibody repertoires for each of donors #1-5, for each of 479 
the two mutational models generated as described in the previous paragraphs. Thus we simulated 480 
a total of 150 personalized replacement-silent antibody repertoires in silico, and 150 out-of-frame 481 
mutational model antibody repertoires, for a total of 300 simulated repertoires with an average of 482 
27,000 antibodies each. Thus, we generated approximately 8,100,000 antibodies in silico and used 483 
the resulting data to explore hypotheses related to mutational targeting in experimental antibody 484 
data compared with simulated datasets. 485 
 486 
Personalized MHC-II Peptide Epitope Content Analysis 487 
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netMHCIIpan MHC-II peptide epitope content predictions were analyzed following the same 488 
procedures as donor repertoires. Isotype assignments for modeled repertoire subsets were made by 489 
matching the SHM distribution by isotype observed in donor-matched experimental data. Next, 490 
heavy and light chain V-gene pairs with n<9 antibodies were removed from analysis. To compare 491 
MHC-II peptide epitope removal in experimental and computationally modeled antibody 492 
repertoire data, isotype-switched, statistically significant VH:VKL gene pairs were retrieved from 493 
donor data and modeled repertoires. These pairs in donor and modeled data were matched in 494 
modeled and donor data, respectively. The number of significant VH:VKL pairs was also 495 
compared between donor and modeled repertoires. For modeled data, the average number of 496 
statistically significant pairs was calculated by dividing the total number of statistically significant 497 
pairs across all modeled repertoires by the number of repertoires (n=30 modeled repertoires per 498 
donor & model type). Volcano plots of modeled repertoires in Figure 3D and S8 were made by 499 
selecting the modeled replicate with an average Spearman Rho value closest to the median 500 
Spearman Rho value of the 30 modeled repertoires from that donor and model type. Statistical 501 
significance was determined by calculating the Spearman correlation and retrieving p-values, that 502 
were adjusted for multiple comparisons using the Benjamini-Holchberg method. For donor 503 
matched vs. mismatched HLA comparisons in Figure S8, the mean Spearman Rho for all V-gene 504 
pairs was calculated for each of the 38 analyzed HLA alleles. The mean Spearman rho for all 38 505 
alleles was shown, with each allele colored according to its supertype family.  506 
 507 
IEDB Data Mining 508 
We searched for experimentally validated antibody-derived peptides in the Immune Epitope 509 
Database (www.iedb.org). The search was limited to linear epitopes from human origin, with 510 
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experimental validation of the binding to MHC II, and from immunoglobulin sequences. After 511 
removing peptides derived from constant regions and T cell receptors, and selecting assays for 512 
HLA-DRB1 molecules, a final database of 448 peptides was obtained. These peptides were 513 
searched for matches in the germline and donor database. As IEDB-validated peptides are of 514 
variable length and whereas our germline/donor peptide databases are exclusively 15-mers, the 515 
presence of validated peptides as substrings in 15-mers was considered a match that is certain to 516 
contain the MHC-II peptide binding core. The same procedure was carried out for HLA-DP and 517 
HLA-DQ molecules, and a total of 187 peptides were found in the IEDB-validated peptide 518 
database.  519 
 520 
Serum Antibody Analysis 521 
From consensus sequences, MHC-II peptide epitope prediction was carried out using 522 
netMHCIIpan and processed as previously indicated. For the cellular and serum antibody analysis 523 
in Fig. 4C [40], data were mined from a recent study of serum antibody prevalence in healthy 524 
donors and antibodies with an total extracted-ion chromatogram (XIC) peak area on the top 50% 525 
for any of the time points analyzed.  526 
Since the HLA alleles for these donors are unknown, all 38 alleles were considered for analysis. 527 
To this end, mean KD was compared between cellular and serum repertoires, and between multiple 528 
observation and single observation antibodies .  529 
 530 
HLA-DR1 Binding Assay 531 
HLA-DR1 (DRA*01:01/DRB1*01:01) extracellular domains were expressed in Drosophila 532 
S2 cells and purified by immunoaffinity chromatography with LB3.1 antibody followed by 533 
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Superdex200 (GE Healthcare) size exclusion chromatography as described [65, 66]. Ig-derived 534 
peptides and influenza HA306-318-derived probe peptide Ac-PRYVKQNTLRLAT were 535 
synthesized (21st Century Biochemicals, Marlboro, MA). The probe peptide was labeled with 536 
Alexa Fluor 488 tetrafluorophenyl ester (Invitrogen, Eugene, OR) through primary amine of K5. 537 
Peptide binding was monitored using a fluorescence polarization assay [67]. The DR1 538 
concentration used was selected by titrating DR1 against fixed labeled peptide concentration (25 539 
nM) and choosing the concentration of DR1 that showed ~50% maximum binding. For calculating 540 
IC50 values, 100 nM DR1 was incubated with 25 nM Alexa488-labeled HA306–318 probe 541 
peptide, in combination with a serial dilution of test peptides, beginning at 100 µM followed by 2-542 
fold dilutions. The reaction mixture was incubated at 37 °C. The capacity of each test peptide to 543 
compete for binding of probe peptide was measured by FP after 72 h at 37 °C. FP values were 544 
converted to fraction bound by calculating [(FP_sample - FP_free)/(FP_no_comp - FP_free)], 545 
where FP_sample represents the FP value in the presence of test peptide; FP_free represents the 546 
value for free Alexa488-conjugated HA306–318; and FP_no_comp represents values in the 547 
absence of competitor peptide. We plotted fraction bound versus concentration of test peptide and 548 
fit the curve to the equation y = bottom + (top – bottom)/(1 +[pep]/IC50), where [pep] is the 549 
concentration of test peptide, y is the fraction of probe peptide bound at that concentration of test 550 
peptide, IC50 is the 50% inhibitory concentration of the test peptide, top is the maximum fraction 551 
of probe peptide bound, and bottom is the minimum fraction of probe peptide bound. 552 
 553 
Quantification and Statistical Analysis 554 
Statistical analyses were performed using R. When multiple comparisons were performed, we 555 
adjusted the p values using the Benjamini-Horchberg method from the stats package. Sample 556 
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distributions were compared using the Kolmorogov-Smirnov test from the stats package. All 557 
correlations were calculated using the Spearman method from the stats package. Levenshtein 558 
distances between donor and germline peptide were calculated using the stringdist package. 559 
Peptide binding curve fitting was carried out using the nls() function from the stats package, 560 
following the equation y = bottom + (top – bottom)/(1 +[pep]/IC50), as previously described. IC50 561 
and standard deviation values were reported. Differences in the mean Spearman correlation for 562 
VH:VL matched gene pairs was carried out using a paired t-test from the stats package. Differences 563 
in the number of significant VH:VL gene pairs for MHC-I and MHC-II were calculated using the 564 
Wilcoxon rank sum test from the stats package.  565 
 566 
Key Resources Table 567 
 568 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
LB3.1 ATCC Cat#ATCC® HB-298 
   
Bacterial and Virus Strains  
   
Biological Samples   
Healthy adult PMBC (Donors 3 and 5) Vaccine Research Center 
(VRC) 
Sample collection 
protocol, VRC 200 
(NCT00067054) 
   
Chemicals, Peptides, and Recombinant Proteins 






Alexa Fluor 488 tetrafluorophenyl ester Invitrogen, Eugene, OR Cat#A37570 






   
Critical Commercial Assays 
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Deposited Data 
Paired VH:VL sequencing from two healthy donors (Donors 6 
and 7) 
DeKosky, BJ. , Lungu, 
OI. et al (2015) 
BioProject 
(PRNJA315079) 
Paired VH:VL sequencing from three healthy donors (Donors 
1, 2 and 4) 
Ahmed, F., DeKosky, 
BJ., et al. (2021, 
Accepted) 
PRJNA682833 
Paired VH:VL sequencing from three healthy donors (Donors 
3 and 5) 
This study XXXXXXXX 
VH sequencing from cellular and serum antibodies (Serum 
study 1) 




Longitudinal VH sequencing of serum antibodies (Serum 
study 2) 




   
Experimental Models: Cell Lines 
Drosophila S2 cells   
   
Experimental Models: Organisms/Strains 
   
Oligonucleotides 
See Table S1 McDaniel, JR., DeKosky, BJ,. 
et al (2016) 
McDaniel, JR., DeKosky, 
BJ,. et al (2016) 
   
Recombinant DNA 
   
Software and Algorithms 
R version 3.53 R Core Team (2019) https://www.R-
project.org/ 









MixCR version 3.012 Bolotin, D.A. (2015) https://mixcr.readthedo
cs.io/en/master/index.h
tml 
IgBlast version 1.16 Ye, J., et al (2013) https://www.ncbi.nlm.
nih.gov/igblast/ 
Usearch version 6.1.544 R.C. Edgar (2010) https://drive5.com/usea
rch/ 









EpiMatrix Schafer, J.R., et al 
(1998) 
https://epivax.com/i 
ImmuneSim version 0.8.7 Weber, C.R., et al (2020) https://immunesim.rea
dthedocs.io/en/latest/ 
ShaZam version 0.23 Gupta, N.T., et al (2015) https://shazam.readthe
docs.io/en/stable/ 
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Stringdist version 0.9.5.5 MPJ van der Loo (2014) https://github.com/mar
kvanderloo/stringdist 
   
Other   
 
 569 
  570 
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Main Figures 571 
 572 
Figure 1. Decreased MHC-II peptide epitope content is correlated with SHM in B cell 573 
receptors, with stronger effects in certain V-genes. A. Overview of MHC-II peptide epitope 574 
characterization in natively paired heavy and light chain human antibody sequence repertories. 575 
Paired heavy and light chain antibody repertoire data were generated by ultra-high throughput 576 
single cell sequencing of B cells from healthy donor PBMCs. An overlap-extension RT-PCR pairs 577 
antibody heavy and light chain variable region (VH and VL) transcripts for NGS analysis. V(D)J 578 
annotation and somatic hypermutation (SHM) assignment was carried out using IgBlast. MHC-II 579 
peptide epitope content of BCR variable regions was analyzed for antibody sequence repertoires 580 
using the EpiMatrix and netMHCIIpan algorithms. MHC-II peptide epitope content metrics were 581 
cross-referenced with SHM and antibody isotype to characterize relationships between MHC-II 582 
peptide epitope content and sequence-based markers of B cell development. B. Scatter plots of 583 
EpiMatrix MHC-II binding prediction scores vs. SHM, based on aggregate data for human 584 
supertype alleles DRB1*01:01, DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*08:01, 585 
DRB1*11:01, DRB1*13:02 and DRB1*15:01. Each point represents an antibody sequence; points 586 
are colored according to data density (yellow: high, purple: low). Linear regressions are shown in 587 
red. p-value of the Spearman correlation is indicated. C. Volcano plots of spearman ρ vs. 588 
Benjamini-Hochberg adjusted p-values for MHC-II peptide epitope content vs. SHM, for antibody 589 
repertoires binned by IGHV and IGKV/IGLV gene pairs. Statistically significant pairs are shown 590 
in blue, and other gene pairs are shown in gray. D. Scatter plots of selected IGHV gene and 591 
IGKV/IGLV gene pairs for SHM vs. predicted binding scores. Linear regression lines are shown 592 
in blue. 593 
 594 
Figure 2. V-gene dependence is driven by the deletion of high affinity peptides present in 595 
germline sequences. A. Repertoire-scale data analysis schematic using netMHCIIpan to identify 596 
patient-specific MHC-II peptide epitopes according to known donor HLA genes. B. Volcano plots 597 
of Spearman ρ vs. Benjamini-Hochberg adjusted p-values for antibody SHM vs. geometric mean 598 
KD fold-change from germline KD, as predicted by netMHCIIpan. Data were grouped by IGHV 599 
gene and IGKV/IGLV gene pairings and analyzed for peptides derived from germline-encoded 600 
MHC-II binding peptides (predicted germline KD <1,000 nM). Statistically significant IGHV gene 601 
and IGKV/IGLV combinations are shown in blue, other gene pairs are shown in gray. C. Scatter 602 
plots of antibody data for selected IGHV and IGKV/IGLV gene pairs displaying antibody SHM 603 
vs. predicted peptide geomean KD fold-change from germline KD. Linear regressions are shown in 604 
blue. D. Geometric mean of the rank percentage, as defined by netMHCIIpan of each putative 605 
peptide across the IGHV sequence, comparing germline IGHV gene (black) and high SHM (top 606 
5%, blue) from the IGHV gene-controlled repertoire. E. Logograms of high affinity germline-607 
encoded peptide residues comparing germline and high SHM antibodies at those residues (top 608 
5%). n represents the number of unique peptides displayed in the high SHM subset. F. 609 
netMHCIIpan KD prediction for peptides shown in the logograms, using one of the donor-specific 610 
HLA-DRB1 alleles. Peptides from Donors 1-3 are shown. G. Experimental validation of peptide 611 
binding affinity to HLA II DRB1 molecules, using a competition assay with peptides derived from 612 
Donor 1. IC50 was calculated using a log-logistic equation. Somatic hypermutations are highlighted 613 
in bold script.  614 
 615 
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Figure 3. Sequence data comparisons with in silico SHM models, and a separate analysis of 616 
MHC-I vs. MHC-II epitope content, both demonstrate the preferential deletion of human 617 
MHC-II peptide epitopes by SHM. A. VH gene usage between experimentally-derived Donor 1 618 
data and Donor 1 modeled antibody repertoires, incorporating both the donor-specific 619 
Replacement-Silent (R-S) SHM model based on Donor 1’s repertoire data, and the universal Out-620 
of-Frame (OoF) SHM model. Gene usage is shown as frequency of the total antibody repertoire. 621 
The same data for additional donors is provided in Figure S7A. B. Distribution of SHM between 622 
Donor 1 experimentally-derived data and in silico modeled repertoires. Black dots represent 623 
outliers. The same data for additional donors is provided in Figure S7B. C. Number of statistically 624 
significant (adjusted p<0.05) IGHV and IGKV/IGLV gene pairs in experimentally-derived donor 625 
data, divided by the average number of significant gene pairs in donor-matched modeled R-S 626 
repertoires (n=30 modeled RS repertoires for each donor). Values >1 indicate that experimentally-627 
derived donor data has more statistically significant heavy:light gene pairs with deleted MHC-II 628 
peptide epitopes from the antibody variable region via SHM. D. Volcano plots of Spearman ρ vs. 629 
Benjamini-Hochberg adjusted p-values for SHM vs. geometric mean KD fold-change from 630 
germline KD in IGHV and IGKV/IGLV gene pairs, as predicted by netMHCIIpan, for isotype-631 
switched antibody sequences. Data were calculated for peptides derived from germline-encoded 632 
high-affinity binders (<1,000 nM). Statistically significant IGHV and IGKV/IGLV gene pairs are 633 
shown in blue, other gene pairs are shown in gray. Experimental donor data and R-S models are 634 
shown. For R-S simulations, 30 repertoires were modeled for each donor for each simulation type, 635 
and the model closest to the median Spearman Rho of all 30 simulations is shown. E. Isotype-636 
switched VH:VKL gene pairs with a significant correlation between KD change and SHM in donor 637 
data and modeled repertoires were retrieved. For donor data, the gene pair list was matched in the 638 
modeled repertoires, and vice versa. The Spearman rho correlation was compared between donor 639 
and modeled repertoires using a paired t-test. F. Upper: The number of significant VH:VL gene 640 
pairs for MHC-I vs. MHC-II peptide epitopes; each point is a different MHC gene:donor 641 
combination. Peptide epitopes were binned as being both an MHC-I+MHC-II (shared) epitope, a 642 
unique MHC-I, or a unique MHC-II epitope, based on donor genotype. Lower: Comparison of 643 
Spearman correlations (KD fold-change vs SHM) between MHC peptide epitope bins for 644 
significant VH:VL gene pairs. *:p<0.05, ***:p < 0.001, N.S: Not significant, Wilcoxon rank sum 645 
test. 646 
 647 
Figure 4. Isotype class switching and antibody secretion as long-lived serum IgG are 648 
correlated with lower MHC-II peptide epitope content in BCRs. A. Antibody repertoires were 649 
fractionated by isotype, and Spearman correlations were calculated for each repertoire subset. 650 
EpiMatrix binding scores are shown as aggregate binding score for supertype alleles DRB1*01:01, 651 
DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*08:02, DRB1*11:01, DRB1*13:02 and 652 
DRB1*15:01. Each point represents a BCR sequence, and points are colored by data density 653 
(yellow: high, purple: low). Linear regressions are shown in red; p-value of the Spearman 654 
correlation is indicated. B. Volcano plot of Spearman ρ vs. Benjamini-Hochberg adjusted p-values 655 
for SHM vs. MHC-II binding score for repertoires grouped by isotype. Data are shown for all 656 
seven donors. C. Geometric mean of the KD comparison for antibody variable region peptides 657 
encoded by cellular vs. serum antibody repertoires, determined using netMHCIIpan. KD for 658 
complete antibodies was obtained from peptides derived from germline peptides with KD <1,000 659 
nM. ‘Serum’ antibody clones were detected in human blood via serum proteomics in a previously 660 
reported study; ‘Cellular’ antibody sequences were restricted to the cellular compartment [40]. 661 
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Differences between groups were analyzed using a t-test. Each point represents the BCR repertoire 662 
MHC-II peptide geomean KD for a human HLA allele (modeled for 38 human alleles, because 663 
donor HLAs are unknown); and alleles with adjusted p<0.05 are shown in red. D. Left Single vs. 664 
Multiple observation antibodies from longitudinal serum repertoire data, plotted as described in 665 
Panel C. Multiple observation antibody clones were detected at multiple time points via serum 666 
proteomics, whereas single observation antibodies were detected only at a single time point [41]. 667 
Right Geomean KD fold-change comparison between Multiple vs. Single observation serum 668 
antibodies E. Proposed mechanism of in vivo selection for BCRs with lower MHC-II peptide 669 
epitopes. Unmutated B cells in germinal centers often express unmutated BCRs that encode high-670 
affinity MHC-II peptides. These high-affinity MHC-II peptides from the BCR can display on 671 
surface MHC-II after endocytosis of the BCR-antigen complex and compete with antigen-derived 672 
peptides for MHC-II surface presentation. Competition between BCR MHC-II peptides and 673 
antigen MHC-II peptides provides a selective pressure for B cells to mutate high-affinity MHC-II 674 
peptide epitopes in the BCR variable region to enhance CD4+ T cell help. Efficient T cell help 675 
leads to further SHM, isotype switching, and the generation of long-lived plasma cells that secrete 676 
an antibody repertoire with decreased MHC-II peptide epitope content.  677 
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Supplementary Figures 678 
 679 
Figure S1. SHM correlates with decreased MHC-II peptide epitope content in B cell 680 
receptors, with stronger effects in certain V-genes. A. Scatter plots of somatic hypermutation 681 
levels (SHM) and EpiMatrix prediction of MHC II binding, as aggregate binding score for 682 
supertype alleles DRB1*01:01, DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*08:02, 683 
DRB1*11:01, DRB1*13:02 and DRB1*15:01. Each point represents an antibody sequence; points 684 
are colored according to data density (yellow: high, purple: low). Linear regressions are shown in 685 
red. p-value of the Spearman correlation is indicated. B. Volcano plots of spearman ρ vs. 686 
Benjamini-Hochberg adjusted p-values for SHM vs. MHC-II peptide epitope content, for 687 
antibodies repertoires grouped by IGHV and IGKV/IGLV gene pairs. Statistically significant pairs 688 
are shown in blue, and other gene pairs are shown in gray. C. Scatter plots of selected IGHV gene 689 
and IGKV/IGLV gene pairs for SHM vs. predicted binding scores. Linear regression lines are 690 
shown in blue. 691 
 692 
Figure S2. Germline MHC-II peptide epitope content varies by IGHV and IGLV/IGKV 693 
genes. Predicted MHC-II binding score was calculated using EpiMatrix for complete donor 694 
repertoires, and divided into V-gene subsets. Higher scores indicate higher content of MHC-II 695 
DRB1 peptide epitopes in the germline V-gene. V-genes were plotted in alphanumerical order, 696 
and the mean of scores (black points) and range (gray lines) are displayed together.  697 
 698 
Figure S3. Germline MHC-II peptide epitope content varies according to HLA-DRB1 gene 699 
profile. MHC-II peptide epitope content was predicted for a database of germline-encoded VH, 700 
VK and VL genes for each HLA-DRB1 allele encoded by donors in this study netMHCIIpan. The 701 
geometric means of the rank percentage for all IGHV- and IGKV/IGLV genes were calculated 702 
(black line) and the range of ranks (0.01%-100%) for peptides centered in each residue is shown 703 
in shaded gray. A lower rank indicates higher peptide:MHC-II binding affinity.  704 
  705 
Figure S4. V-gene dependence is driven by deletion of high affinity peptides present in 706 
germline sequences. A. Volcano plots of Spearman ρ vs. Benjamini-Hochberg adjusted p-values 707 
for antibody SHM vs. geometric mean KD fold-change from germline KD, as predicted by 708 
netMHCIIpan. Data were grouped by IGHV gene and IGKV/IGLV gene pairings and analyzed for 709 
peptides derived from germline-encoded MHCII binding peptides (predicted germline KD <1,000 710 
nM). Statistically significant IGHV gene and IGKV/IGLV combinations are shown in blue, other 711 
gene pairs are shown in gray. B. Scatter plots of antibody data for selected IGHV and IGKV/IGLV 712 
gene pairs displaying antibody SHM vs. predicted peptide geomean KD fold-change from germline 713 
KD. Linear regressions are shown in blue. C. Geometric mean of the rank percentage, as defined 714 
by netMHCIIpan of each putative peptide across the IGHV sequence, comparing germline IGHV 715 
gene (black) and high SHM (top 5%, blue) from the IGHV gene-controlled repertoire. D. 716 
Logograms of high affinity germline-encoded peptide residues comparing germline and high SHM 717 
antibodies at those residues (top 5%). n represents the number of unique peptides displayed in the 718 
high SHM subset. E. netMHCIIpan KD prediction for peptides shown in the logograms, using one 719 
of the donor-specific HLA-DRB1 alleles. Donors 4 and 5 are shown. Figure S5. Experimental 720 
observation of key antibody peptides in immunopeptidomic assay data in IEDB. A. 721 
Observations of IGHV-derived peptides experimentally confirmed to be immune epitopes and 722 
displayed by residue position. Data was retrieved from the Immune Epitope Database and analysis 723 
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resource (IEDB, www.iedb.org). B. Presence of confirmed MHC-II peptide epitopes in antibody 724 
repertoires. Peptides eluted from MHC-II molecules were retrieved from IEDB and used as a 725 
search database to mine donor repertoire data. IEDB peptides present both as substrings entirely 726 
contained within antibody 15-mers, and complete 15-mer matches, were accepted. C. Overlap 727 
between confirmed HLA-DRB1 peptides and HLA-DP/DQ peptides from antibody V-genes found 728 
in IEDB. Antibody peptides detected in the IEDB HLA-DRB1 database were searched in the HLA-729 
DP/DQ database, accepting only complete matches.  730 
 731 
Figure S6. netMHCIIpan data analysis, computational repertoire modeling, and 732 
personalized repertoire analytics. A. Data processing using netMHCIIpan. Upper panel The 733 
presence of MHC-II peptide epitopes was determined in donor data for the complete set of 38 734 
HLA alleles. HLA typing was also carried out. Middle panel Somatic hypermutation models 735 
ShaZam and immuneSIM were used to simulate 30 repertoires, with the same number of BCR 736 
sequences as experimentally-derived donor data. SHM distribution and V-gene frequencies were 737 
calculated. Lower panel The subset of peptides with MHC-II KD<1,000 nM to any of the 38 738 
alleles were selected to generate a database of potential predicted binders. B. Using the germline 739 
peptide database, peptides at the same position within the V-region were extracted from 740 
experimentally-derived donor data or simulated repertoires and grouped according to parent 741 
antibody V-gene. The fold-change between repertoire-scale BCR geomean[peptide:MHC-II KD] 742 
and germline geomean[peptide:MHC-II KD] was calculated and aggregated by V-gene. The 743 
Spearman correlation between KD fold-change and SHM was calculated for each V-gene. These 744 
data was used for the plots shown in Figure 2A. C. Using correlation data from B, significant 745 
(adjusted p <0.05) and strong ( > 0.5 ) correlations were extracted and averaged by allele. 746 
Alleles were plotted according to their individual geomean Spearman ρ scores, with the larger 747 
circles corresponding to each of the donor’s two HLA-DRB1 alleles.  748 
 749 
Figure S7. IGHV gene usage and SHM distribution for each experimentally-derived BCR 750 
repertoire data, universal Out-of-frame (OoF) modeled repertoire data, and donor-specific 751 
Replacement-Silent (RS) modeled repertoire data. A. IGHV gene usage between Donors 2-5 752 
experimentally-derived repertoires and OoF and RS modeled repertoires. Gene usage is shown as 753 
frequency of total repertoire. B. SHM distribution for Donors 2-5 experimentally-derived 754 
repertoires and OoF and RS modeled repertoires. Black dots represent outliers. 755 
 756 
Figure S8. Somatic hypermutations selectively delete MHC-II peptide epitopes. A. 757 
Levenshtein distance between donor and germline peptide was calculated as a measure of 758 
mutational load. The number of mutations was plotted against the KD fold-change between donor 759 
and germline peptides for donor-matched alleles. Outliers were removed for visualization but not 760 
for calculation of quartiles for boxplot generation B. Volcano plots of Spearman ρ vs. Benjamini-761 
Hochberg adjusted p-values for SHM vs. geometric mean KD fold-change from germline KD, as 762 
predicted by netMHCIIpan. Data were calculated for peptides derived from germline-encoded 763 
high-affinity binders (< 1,000 nM). Statistically significant IGHV and IGKV/IGLV gene pairs are 764 
shown in blue, other gene pairs are shown in gray. Donor, OoF and R-S models are shown. For 765 
OoF and R-S simulations, 30 repertoires were modeled for each donor, and the model closest to 766 
the median Spearman Rho of all 30 simulations is shown. C. Number of statistically significant 767 
(adjusted p < 0.05) IGHV and IGKV/IGLV gene pairs in experimentally-derived donor data, 768 
divided by the average number of significant gene pairs in donor-matched modeled OoF 769 
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repertoires (n=30 modeled OoF repertoires for each donor). Values >1 indicate that 770 
experimentally-derived donor data has more statistically significant gene pairs that show decreased 771 
MHC-II peptide epitope content by SHM. “All alleles” reports the average of all 10 HLA-DRB1 772 
alleles from the 5 donors, “Top alleles” reports the average of the top HLA-DRB1 allele collected 773 
from each donor. D. Spearman Rho comparison of aggregated HLA molecules. Alleles were 774 
clustered according to supertypes as defined in [60]. The Spearman ρ geometric mean was 775 
calculated for every allele, and then for all supertypes. Each color represents a different supertype. 776 
Supertypes with donor-matched HLA molecules are shown as bigger circles. E. Isotype-switched 777 
VH:VKL gene pairs with a significant correlation between KD change and SHM in donor data and 778 
modeled repertoires were retrieved. For donor data, the gene pair list was matched in the modeled 779 
repertoires, and vice versa. Spearman rho correlations were compared between donor and modeled 780 
repertoires using a paired t-test.  781 
 782 
Figure S9. Isotype class switching is correlated with preferential removal of MHC-II peptide 783 
epitopes from BCRs. A. Antibody repertoires were fractionated by isotype, and Spearman 784 
correlations were calculated for each repertoire subset. EpiMatrix binding scores are shown as 785 
aggregate binding score for supertype alleles DRB1*01:01, DRB1*03:01, DRB1*04:01, 786 
DRB1*07:01, DRB1*08:01, DRB1*11:01, DRB1*13:02 and DRB1*15:01. Each point represents 787 
a BCR sequence, and points are colored by data density (yellow: high, purple: low). Linear 788 
regressions are shown in red; p-value of the Spearman correlation is indicated.  789 
 790 




Oligonucleotide name Oligonucleotide sequence Source 
IgM Constant Region CGCAGTAGCGGTAAACGGCCACAGGAGACGAGGGGGAAA McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgG Constant Region CGCAGTAGCGGTAAACGGCAGGGYGCCAGGGGGAAGAC McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgA Constant Region CGCAGTAGCGGTAAACGGCCGGGAAGACCTTGGGGCTGG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgLC Constant Region GCGGATAACAATTTCACACAGGTCCTCAGAGGAGGGYGGGA
A 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgKC Constant Region GCGGATAACAATTTCACACAGGGATGAAGACAGATGGTGCA
G 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH1 FR1 Region TATTCCCATCGCGGCGCCAGGTCCAGCTKGTRCAGTCTGG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH157 FR1 Region TATTCCCATCGCGGCGCCAGGTGCAGCTGGTGSARTCTGG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH2 FR1 Region TATTCCCATCGCGGCGCCAGRTCACCTTGAAGGAGTCTG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH3 FR1 Region TATTCCCATCGCGGCGCGAGGTGCAGCTGKTGGAGWCY McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH4 FR1 Region TATTCCCATCGCGGCGCCAGGTGCAGCTGCAGGAGTCSG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH4-DP63 FR1 Region TATTCCCATCGCGGCGCCAGGTGCAGCTACAGCAGTGGG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH6 FR1 Region TATTCCCATCGCGGCGCCAGGTACAGCTGCAGCAGTCA McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VH3N FR1 Region TATTCCCATCGCGGCGCTCAACACAACGGTTCCCAGTTA McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VK1 FR1 Region GCGCCGCGATGGGAATAGCTAGCCGACATCCRGDTGACCCA
GTCTCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VK2 FR1 Region GCGCCGCGATGGGAATAGCTAGCCGATATTGTGMTGACBCA
GWCTCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
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VK3 FR1 Region GCGCCGCGATGGGAATAGCTAGCCGAAATTGTRWTGACRCA
GTCTCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VK5 FR1 Region GCGCCGCGATGGGAATAGCTAGCCGAAACGACACTCACGCA
GTCTC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL1 FR1 Region GCGCCGCGATGGGAATAGCTAGCCCAGTCTGTSBTGACGCAG
CCGCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL1459 FR1 Region GCGCCGCGATGGGAATAGCTAGCCCAGCCTGTGCTGACTCAR
YC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL15910 FR1 Region GCGCCGCGATGGGAATAGCTAGCCCAGCCWGKGCTGACTCA
GCCMCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL2 FR1 Region GCGCCGCGATGGGAATAGCTAGCCCAGTCTGYYCTGAYTCA
GCCT 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL3 FR1 Region GCGCCGCGATGGGAATAGCTAGCCTCCTATGWGCTGACWCA
GCCAA 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL-DPL16 FR1 Region GCGCCGCGATGGGAATAGCTAGCCTCCTCTGAGCTGASTCAG
GASCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL3-38 FR1 Region GCGCCGCGATGGGAATAGCTAGCCTCCTATGAGCTGAYRCAG
CYACC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL6 FR1 Region GCGCCGCGATGGGAATAGCTAGCCAATTTTATGCTGACTCAG
CCCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
VL78 FR1 Region GCGCCGCGATGGGAATAGCTAGCCCAGDCTGTGGTGACYCA
GGAGCC 
McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgG Constant Region 
nested 
NNNNATGGGCCCTGSGATGGGCCCTTGGTGGARGC McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgM Constant Region 
nested 
NNNNATGGGCCCTGGGTTGGGGCGGATGCACTCC McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgA Constant Region 
nested 
NNNNATGGGCCCTGCTTGGGGCTGGTCGGGGATG McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgKC Constant Region 
nested 
NNNNGTGCGGCCGCAGATGGTGCAGCCACAGTTC McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
IgLC Constant Region 
nested 
NNNNGTGCGGCCGCGAGGGYGGGAACAGAGTGAC McDaniel, JR., DeKosky, BJ,. et al 
(2016) 
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Peptide Sequence IC50 ± S.D
S1 - Germline NTLYLQMNSLRAE 62.3 ± 14.6
S1 - Peptide 1 NTVFLQMHSLRDE 1100 ± 301
S1 - Peptide 2 SSVYLQMNDLRVE 2077 ± 1106
S1 - Peptide 3 NTLYLHMSGLRDE 863 ± 296
S2 - Germline TLYLQMNSLRAED 56.3 ± 8.5
S2 - Peptide 1 TVSLQLNSLRADD 490 ± 111
S2 - Peptide 2 TLYLQMNRLRADD 387 ± 91
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Serum Study 2 - Donor A
p-value = 0.05
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